Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture

NCT01292187 is registered in ClinicalTrials.gov with Tarsa Therapeutics, Inc. as lead sponsor.

NCT NCT01292187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01292187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Lead sponsor
Tarsa Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2011
Completion date
July 31, 2012
Enrollment
129 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

osteopenia